These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1867 related articles for article (PubMed ID: 26207888)

  • 21. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
    Roskoski R
    Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
    Roskoski R
    Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
    Roskoski R
    Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies.
    Roskoski R
    Pharmacol Res; 2021 Jun; 168():105579. PubMed ID: 33774181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States.
    Roskoski R
    Pharmacol Res; 2023 Aug; 194():106847. PubMed ID: 37454916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hydrophobic and polar interactions of FDA-approved small molecule protein kinase inhibitors with their target enzymes.
    Roskoski R
    Pharmacol Res; 2021 Jul; 169():105660. PubMed ID: 33971270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs).
    Roskoski R
    Pharmacol Res; 2021 Mar; 165():105422. PubMed ID: 33434619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update.
    Roskoski R
    Pharmacol Res; 2022 Jan; 175():106037. PubMed ID: 34921994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rule of five violations among the FDA-approved small molecule protein kinase inhibitors.
    Roskoski R
    Pharmacol Res; 2023 May; 191():106774. PubMed ID: 37075870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms.
    Roskoski R
    Pharmacol Res; 2016 Nov; 113(Pt A):395-408. PubMed ID: 27641927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition.
    Roskoski R
    Pharmacol Res; 2013 Feb; 68(1):68-94. PubMed ID: 23201355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA; Wilhelm S; Carter C; Kelley SL
    Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of tyrosine kinase inhibitors in cancer therapy.
    Arora A; Scholar EM
    J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Tyrosine kinase inhibitors for the treatment of CML].
    Heim D
    Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Probing cAMP-dependent protein kinase holoenzyme complexes I alpha and II beta by FT-IR and chemical protein footprinting.
    Yu S; Mei FC; Lee JC; Cheng X
    Biochemistry; 2004 Feb; 43(7):1908-20. PubMed ID: 14967031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update.
    Roskoski R
    Pharmacol Res; 2023 Jan; 187():106552. PubMed ID: 36403719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mapping intersubunit interactions of the regulatory subunit (RIalpha) in the type I holoenzyme of protein kinase A by amide hydrogen/deuterium exchange mass spectrometry (DXMS).
    Hamuro Y; Anand GS; Kim JS; Juliano C; Stranz DD; Taylor SS; Woods VL
    J Mol Biol; 2004 Jul; 340(5):1185-96. PubMed ID: 15236976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
    Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
    Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 94.